Aldeyra Therapeutics, Inc.
Reproxalap
Dry Eye Disease
Resolved
7days ago
Catalyst readout · ~ Jun 30, 2026 estimated
What's at stake
A key catalyst for Reproxalap (Dry Eye Disease) is expected ~ Jun 30, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Type A meeting with the FDA is expected to be held in the second quarter of 2026”